SCHEMBL4300569

SCHEMBL4300569

O=c1[nH]c2cc(Cl)ccc2cc1-c1nc2ccccc2[nH]1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.74
PDGFRB P09619 1/20 0.74
FGFR1 P11362 1/20 0.74
NPC1 O15118 7/20 0.52
RAB9A P51151 7/20 0.52
KDM4E B2RXH2 6/20 0.52
ALDH1A1 P00352 3/20 0.52
GPR55 Q9Y2T6 1/20 0.52
GBA1 P04062 1/20 0.51
MAPT P10636 2/20 0.50
TP53 P04637 2/20 0.50
HSD17B10 Q99714 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
CYP3A4 P08684 1/20 0.50
HPGD P15428 1/20 0.50
MAPK1 P28482 1/20 0.50
FTO Q9C0B1 1/20 0.50
GUSB P08236 1/20 0.50
AMY1A P0DUB6 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3501686 0.89 KDR (0.74) KDRPDGFRBFGFR1NPC1RAB9A
SCHEMBL29394784 0.89 KDR (0.74) KDRPDGFRBFGFR1NPC1RAB9A
SCHEMBL3503147 0.86 KDR (1.00) KDRPDGFRBFGFR1NPC1RAB9A
SCHEMBL3501208 0.85 KDR (0.72) KDRPDGFRBFGFR1NPC1RAB9A
SCHEMBL4298828 0.84 KDR (0.74) KDRPDGFRBFGFR1NPC1RAB9A
SCHEMBL6159003 0.84 KDR (0.74) KDRPDGFRBFGFR1NPC1RAB9A
SCHEMBL3501389 0.81 KDR (0.69) KDRPDGFRBFGFR1NPC1RAB9A
SCHEMBL3503448 0.81 KDR (0.69) KDRPDGFRBFGFR1NPC1RAB9A
SCHEMBL3499041 0.81 KDR (0.65) KDRPDGFRBFGFR1NPC1RAB9A
SCHEMBL21660577 0.80 KDM4E (0.55) KDRPDGFRBFGFR1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090281100-A1 Benzimidazole quinolinones and uses thereof BARSANTI PAUL A 2009-11-12 US disclosed
EP-1226119-B1 TYROSINE KINASE INHIBITORS MERCK & CO INC (US) 2005-03-16 EP disclosed
EP-1226119-A4 TYROSINE KINASE INHIBITORS MERCK & CO INC (US) 2003-04-09 EP disclosed
US-6479512-B1 TO TREAT TYROSINE KINASE-DEPENDENT DISEASES AND CONDITIONS, SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, ETC. MERCK & CO., INC. 2002-11-12 US disclosed
EP-1226119-A2 TYROSINE KINASE INHIBITORS MERCK & CO. INC. (US) 2002-07-31 EP disclosed
WO-2001028993-A2 TYROSINE KINASE INHIBITORS MERCK & CO. INC. (US) 2001-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281100-A1 Benzimidazole quinolinones and uses thereof GAA, ALPI, IL4I1 KDR 4671/4885PDGFRB 3508/4885FGFR1 3018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.